---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-23-001588"
form_type: "8-K"
ticker: "IDXX"
cik: "0000874716"
company_name: "IDEXX LABORATORIES INC /DE"
filed_at: "2023-11-01T23:59:59+00:00"
generated_at: "2026-06-09T03:44:20.617490+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# IDEXX Q3 revenue $916M (+9% reported); EPS $2.53; FY guidance updated to $3.635-$3.65B

## Summary
- Q3 revenue $916M (+9% reported, +8% organic) driven by CAG Diagnostics recurring revenue +10% reported (+9% organic).
- EPS $2.53, up 18% reported (16% comparable); operating margin 30.1% (expanded 100bps reported, 140bps comparable).
- FY2023 revenue guidance lowered to $3,635-$3,650M (7.9%-8.4% growth); EPS outlook raised to $9.74-$9.90 (midpoint +$0.05).
- Global premium instrument installed base grew 11% YoY; VetLab consumables revenue +11% organic.
- Water revenue +7% organic; Livestock/Poultry/Dairy revenue +2% organic; solid gains in U.S. offset international headwinds.

## SEC filing metadata
- accession: 0001157523-23-001588
- form_type: 8-K
- ticker: IDXX
- cik: 0000874716
- company_name: IDEXX LABORATORIES INC /DE
- filed_at: 2023-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874716/000115752323001588/0001157523-23-001588-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874716/000115752323001588/a53720791.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-23-001588
- JSON: https://secwatch.observer/filing/0001157523-23-001588.json
- Plain text: https://secwatch.observer/filing/0001157523-23-001588.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.